

EXPERT OPINION

1. Introduction
2. α -Subtype-selective ligands
3. GABA_A receptor modulators
4. Labeled compounds
5. Patents of natural products and derivatives
6. Expert opinion

Benzodiazepine receptor ligands: a patent review (2006 – 2012)

Gabriella Guerrini[†] & Giovanna Ciciani

Dipartimento di Neuroscienze, Psicologia, Area del Farmaco e Salute del Bambino, NEUROFARBA - “Sezione di Farmaceutica e Nutraceutica” Università degli Studi di Firenze, Italy

Introduction: Ligands at the benzodiazepine site of the GABA_A receptor (GABA_A-R) act by modulating the effect of GABA (γ-aminobutyric acid). The selective modulator effects of such ligands are related to the α -subunits type (i.e., $\alpha 1$, $\alpha 2$, $\alpha 3$, and $\alpha 5$), being shown that the $\alpha 1$ subunit is associated with sedative, anticonvulsant and amnesic effects; whereas the $\alpha 2$ and $\alpha 3$ subunits mediate anxiolytic and myorelaxant effects. Recently it was shown the involvement of $\alpha 5$ subunit in pain relief, which is involved in cognitive processes of learning and memory.

Areas covered: This review covers patents, published from January 2006 to October 2012, on ligands for the benzodiazepine binding site of the GABA_A-Rs. Patents filed from different companies and research groups report many series of compounds that may be used in the treatment or prevention of a large variety of neurodegenerative diseases.

Expert opinion: Most patents highlighted that various memory deficits, related to Alzheimer's disease, Down syndrome, mood disorders, schizophrenia, and age-related cognitive impairment may be treated using $\alpha 5$ -selective ligands. Other aspects related to the use of allosteric modulators of the $\alpha 7$ -nAChR and/or $\alpha 5$ -GABA_A-R (dual approach) for alleviating the impaired cognition and the use of $\alpha 2$ -selective ligands for pain relief are highlighted, being particularly intriguing as new therapeutic approaches.

Keywords: benzodiazepine receptor ligands, cognitive impairment, GABA_A subtype receptor modulators, neurodegenerative diseases, neuropathic pain

Expert Opin. Ther. Patents [Early Online]

1. Introduction

The GABA_A receptors (GABA_A-Rs) are heteropentamer members of the Cys-loop ligand-gated ion channel (LGIC) superfamily permeable to chlorine ions. They are composed of two α -, two β -, and one γ -subunits (despite the 19 total subunits, i.e., $\alpha 1 - 6$, $\beta 1 - 3$, $\gamma 1 - 3$, δ , ϵ , τ , π and $\rho 1 - 3$, that could arrange in enormous number of theoretical pentameric combinations). Recently, Olsen and Sieghart [1] reported the criteria to establish which GABA_A subtype receptors are unequivocally identified in the brain and a list of three categories of native receptor subtypes was suggested, as “identified,” “existence with probability” and “tentative.” Only 9 – 11 different subtypes were identified in the brain up until now [1], but the list is continuously being updated with new information. However the distribution of the “identified” GABA_A-Rs in the brain predicts that the combination $\alpha 1\beta\gamma 2$ is the most abundant type (60%), being located in the cortex, hippocampal neurons, thalamus, and cerebellum. The combination $\alpha 2\beta\gamma 2$ and $\alpha 3\beta\gamma 2$ are moderately abundant (10 – 20%) and they are found in the hippocampal formation, hypothalamus, and amygdale. Finally, the combination $\alpha 5\beta\gamma 2$ is expressed in the hippocampus (pyramidal cells), amygdale, and hypothalamus (5%) [2]. The identity of the β subunits in these combinations is lacking and often cannot be determined, because

informa
healthcare

Article highlights.

- Most of the analyzed patents claim that GABA_A α 5 inverse agonists or α 5 agonists may be useful for memory therapy associated with neurodegenerative diseases.
- An intriguing aspect that was revealed regards the use of α 2/ α 3-selective ligands for the prevention or suppression of neuropathic pain in addition to their anxiolytic effects.
- The use of a dual approach (allosteric modulators of α 7-nAChR and/or α 5-GABA_A-R) is claimed as a therapeutically relevant modality to ameliorate CNS disorders.
- The chemical scaffolds of the claimed drugs show a high degree of heterogeneity and an enhanced flexibility.
- The label strategy is another topic reported in some patents with the aim to obtain a higher metabolic stability or useful diagnostics tools for imaging methods.

This box summarizes key points contained in the article.

of the co-precipitation of all three subunits in immunoprecipitation or electrophysiological studies [3]. However, even if the subunit β 1 is the least common, the β 2 is the most abundant and widespread, whereas the β 3 is more discrete. All β isoforms can exist in functional receptors, and usually as one type per pentamer [3]. Subunits α 4 and α 3 are present in combination with β 2/3 isoforms and with the subunit δ and represent a minor population of receptors in the striatum and cerebellum [4].

The benzodiazepine site on GABA_A-R (alternatively named GABA_A/Bz site, GABA_A subtype receptor, or α _n-containing GABA_A-R basing on the contained α subunit) is one among the numerous “binding sites” in the GABA_A-R. In fact barbiturates, anesthetics, picrotoxin, neurosteroids, alcohol, and Zn²⁺ can bind and directly activate or modulate the receptor function [4]. In particular, benzodiazepine (Bz) and non-benzodiazepine ligands bind the receptor in a site that lies at the interface between the α / γ subunit. These ligands act by modulating the effect of GABA (γ -aminobutyric acid), by increasing the GABA-evoked chlorine current (agonist, positive allosteric modulators [PAM]) or reducing (inverse agonist, negative allosteric modulators [NAM]) or not influencing the chlorine flux (antagonist). The ability of Bz ligands to modulate GABA-mediated channel activity depends on the presence of the γ -subunit in the pentamer, whereas their pharmacological effects are related to the type of the α -subunits [5].

The proven clinical efficacy of the classical benzodiazepines (anxiolytic, anticonvulsant, myorelaxant, and hypnotic) is associated with several side effects such as sedation, memory deficit, dependence, abuse liability and withdrawal syndrome upon cessation of therapy [6]. Thus, the achievement of selective pharmacological effects is a challenge for researchers active in this field and a variety of approaches have been used to better understand the role of the different subunits

in the physiology and pathophysiology of CNS [5]. The attempt to synthesize novel compounds to define the functions of GABA_A-R subtypes met with limited success. The advent of the molecular genetics has delineated new perspectives to define the relationships between the α isoform and the pharmacological effects of the Bz site ligands [3]. The generation of transgenic mouse (knock-in mouse) with a point mutation at the His residue, with Arg at the α 1-3,5 subunits (at position 101 in the α 1- and α 2-subunits, and in homologous residues in the α 3- and α 5-subunits, respectively) produced α _n-subtype receptors insensible to diazepam, and permitted to identify the pharmacological activity of the specific mutate subunit [6]. In this way, it was shown that the α 1 subunit is associated with the sedative, anticonvulsant and amnesic effects of diazepam. The α 2- and α 3-subunits mediate the anxiolytic and myorelaxant effects of diazepam [7], whereas the α 5 subunit is involved in cognitive processes of learning and memory [8]. These evidences support the hypothesis that subtype-selectivity can lead to pharmacological selectivity, allowing thus the obtaining of anxiolytic drugs devoid of sedative effects, as well as procognitive drugs without anxiogenic or convulsant effects [8]. Further genetic studies have been developed mainly with the aim to individuate new roles of the α subunits and to find novel therapeutic opportunities. The obtained results showed that the α 2 subunits are involved in schizophrenia [9,10], depression [11-13] and chronic neuropathic pain [14-21]; the α 5 subunits are involved in cognitive deficits related to aging [22] and to the Down syndrome (DS) [23,24]. With the same aims, other strategies based on multi-targeted therapy [25,26] and labeled drugs [27,28] have been used.

For the purpose of the present review, we have considered World, US and EP Patents filed from Companies, Universities and individual authors between January 2006 and October 2012, related to GABA_A benzodiazepine receptor ligands. The patents were selected from SciFinder data base of Chemical Abstract (C.A.) and from Espacenet and have been grouped according to α -subtype-selective ligands, GABA_A-R modulators, labeled and natural compounds. In case where *in vivo* data were not given, the compounds were chosen based on the *in vitro* data, selecting those compounds that possess the highest affinity value (I%, IC₅₀ or K_i). Otherwise, a description of all pharmacological data (*in vitro* and *in vivo*) was made by the authors of the review.


2. α -Subtype-selective ligands



2.1 Selective α 5 GABA_A inverse agonists

2.1.1 New compounds

Hoffmann-La Roche has filed numerous patent applications in the field of α 5-selective GABA_A ligands. The compounds reported in these patents are useful for neurological disorders and in particular as cognitive enhancers or for therapeutic and/or prophylactic treatment of cognitive disorders such as AD. The affinity of these compounds at GABA_A-R subtype was measured by competition for [³H]flumazenil binding to

Table 1. A list of the patents and representative compounds (Hoffmann-La Roche).



Patent	Compound*	R ₁	R ₂	R ₃	K _i (nM)			
					α5	α1	α2	α3
US2006079507 [29]	33	Br	H		3.8	108.6	159.8	132.7
US2006084642 [30]	6	Br	H	CH ₂ F	8.7	215.0	261.2	107.5
US2006128691 [31]	3	Cl	H	CH ₃	3.0	18.5	218.9	265.2
WO2006045429 [32]	3	OCH ₃	H	Cl	0.8	12.2	17.2	11.7
WO2007042421 [33]	123	Br		CH ₃	0.6	188.1	-	-

*Original number compound used in the cited patents: selection, made by the authors, of the most representative structures.

HEK293 cells expressing rat (stably transfected) or human (transiently transfected) receptors of the composition α1β3γ2, α2β3γ2, α3β3γ2, α5β3γ2 [29-55]. In most cases, the compounds showed selectivity for the α5 subunit with respect to α1, α2 and α3 subunits (Tables 1,2 and 3; binding data to α1, α2 and α3 subunits are reported when available). This company claimed several chemical series related to imidazo[1,5-a][1,2,4]triazolo[4,3-d][1,4]benzodiazepine (Table 1) [29-33], isoxazole (Table 2) [34-53], and triazole derivatives (Table 3) [54,55].

2.1.2 Known compounds

Many companies/institutions reported in their application known α5 inverse agonist ligands that, for the sake of clarity, are grouped in Figure 1. The intellectual property is concerned with the pharmacological, preclinic and clinical studies to evaluate the cognitive impairment caused by various diseases (psychiatric pathologies, DS, AS) or conditions (anesthesia, inflammation, etc.).

The Governing Council of the University of Toronto reports [56] methods for the prevention and or treatment of memory impairment (long- and short-term) arising as a consequence of excessive GABA_A-Rs activation. This increased activation can be caused by administration of an anesthetic or by an increase in interleukine-1β (IL-1β) expression and/or activity, induced by inflammation or surgery. This patent is concerned with the protocols for planning the pharmacological studies and reports several references for each considered aspect. Data obtained from these studies disclosed the

therapeutic utility of the α5 inverse agonists. In particular, L655708 [57] reverses memory deficit after exposure to the anesthetic isoflurane and MRK-016 [58] reverses the memory deficit associated with inflammation, both in young and aging brain.














The invention of Cambridge Enterprise Ltd. [59], reports to the treatment of impaired cognitive function in patients with psychiatric conditions. In treated patients, the use of flumazenil [60] improved cognitive performance, whereas healthy individuals treated in the same way showed a slightly impaired performance.

The Centre National De la Recherche Scientifique (CNRS) has deposited an application [61] in which the known compounds L655708, MRK-016, RO4938581 [62], α₅IA [8], having inverse agonist functional selectivity for GABA_A-Rs containing α₅ subunit, may possess superior efficacy to treat cognitive impairment associated with DS. This was evaluated by *in vitro* and *in vivo* tests on Ts65Dn mice, a murine model of DS.

The Board of Trustees of the Leland Stanford Junior University [63] reported methods for improving cognitive functions by administration of negative GABA_A-R modulators α₅IA, RO4938581, RO4882224 [62], and GABA_A-R antagonists, as bilobalide, ginkgolide B and picrotoxine. The methods provided in this application consisted in the administration of therapeutically effective doses of selected compounds so that the peak concentration occurred when the subject was asleep.

Wisys Technology Foundation in the Patent US7595395 [64] claimed pharmacological methods for the prevention and/or











Table 2. A list of the patents and representative compounds (Hoffmann-La Roche).

Patent	Compounds*	X	R	R ₁	R ₂	α5 K _i (nM)
WO2007074078 [34]	135	CH			H	1.64
WO2007082806 [35]	68	CH			H	5.5
WO2007074089 [36]	1	CH	CH ₃		H	77.9
WO2007071598 [37]	127	CH	CH ₃		H	1.7
US2007105922 [38]	21	CH	CH ₃		H	1.4
US2007066668 [39]	162	CH	CH ₃		Cl	1.4
WO2007137954 [40]	50	CH	CH ₃		H	7.3
WO2009000662 [41]	40	CH	CF ₃		F	4.1
WO2009071476 [42]	311	N	CH ₃		Cl	0.1
US2009143385 [43]	102	N	CH ₃		H	0.9
US2009143407 [44]	3	CH	CH ₃		H	1.2

*Original number compound used in the cited patents: selection, made by the authors, of the most representative structures.

†n-butyl is the substituent in 3-position of isoxazole.






Table 2. A list of the patents and representative compounds (Hoffmann-La Roche) (continued).

						
Patent	Compounds*	X	R	R ₁	R ₂	α5 K _i (nM)
WO2010127968 [45]	8	CH	CH ₃		H	6.9
WO2010112475 [46]	19	CH	CH ₂ OH		Cl	0.4
WO2010127974 [47]	69	CH	CH ₃		H	0.3
WO2010127975 [48]	125	CH	CH ₃		F	0.4
WO2010127976 [49]	39	CH	CH ₂ OH		F	0.8
WO2010127978 [50]	23	‡	CH ₃		^	2.2
US2010256154 [51]	12	N	CH ₃		F	0.3
US2010216845 [52]	4	CH	CH ₃		H	2.0
US2010210651 [53]	16	N	CH ₃		H	1.4


*Original number compound used in the cited patents: selection, made by the authors, of the most representative structures.

‡n-butyl is the substituent in 3-position of isoxazole.



Table 3. A list of the patents and representative compounds (Hoffmann-La Roche).

					
Patent	Compounds*	R ₁	R ₂	R ₃	α5 K _i (nM)
WO2012062687 [54]	37		CH ₃		1.7
WO2012076590 [55]	42	CH ₃			3.2


*Original number compound used in the cited patents: selection, made by the authors, of the most representative structures.

**L655708**

WO2012051707 (The Governing Council of The University of Toronto) [56]
 WO2011024115 (Centre National de la Recherche Scientifique-CNRS) [62]

**MRK-016****Flumazenil**

WO2009016329 (Cambridge Enterprise Ltd.) [59]

**RO4938581**

WO2011024115 (Centre National de la Recherche Scientifique-CNRS) [62]
 US20121574445 (The Board of Trustees of the Leland Stanford University) [63]




**α5IA****RO4882224**

Figure 1. Structures of known α5 inverse agonists.

treatment of memory deficit. Among the drugs/compounds used in this patent were the α-5 inverse agonists PWZ029 [65] and XLI356 (Figure 2) [66]. From a full panel of receptor binding was observed that XLI356 does not bind to other types of


receptors and, with PWZ029, were found to reverse scopolamine-induced memory deficit (1 mg/kg) in mice at the dose of 10 mg/kg. XLI356 and PWZ029 were not able to reverse audio cued memory (amygdala-driven) suggesting that the



PWZ-029 K_i (nM) $\alpha 5 = 38.8$; $\alpha 1/\alpha 2/\alpha 3 = 300$

US7595395 (Wisys Technology Foundation) [64]


US20100130479 (Cook) [67]



XLI356 K_i (nM) $\alpha 5 = 107$; $\alpha 1/\alpha 2 > 2000$; $\alpha 3 = \text{NT}$

US7595395 (Wisys Technology Foundation) [64]

Figure 2. Examples of known $\alpha 5$ inverse agonists claimed by Wisys Technology Foundation and James Cook.



Example 1 NAM $\alpha 5$ GABA_A-R; PAM $\alpha 7$ AchR

WO20100104843 (The Regents of the University of California) [68]

Figure 3. Example of compound claimed by The Regents of the University of California.

effects of these compounds may be mediated through $\alpha 5$ receptors located in the hippocampus (highly associated with contextual memory).

This patent has been continuing-in-part of patent application US20100130479 by James Cook [67] in which the compound PWZ029, already studied for its cognitive enhancing effect in rodents, was evaluated as cognitive enhancer in a test of “executive function” in monkeys (Object Retrieval with Detours [ORD]).

2.2 Selective $\alpha 5$ GABA_A inverse agonists and $\alpha 7$ nACh agonists

The Regents of the University of California, taking into account the validity of the multi-targeted therapy, presented an invention [68] of dual compounds as $\alpha 5$ GABA_A-Rs NAM and $\alpha 7$ nAChRs PAM (Figure 3). Electrophysiological methods were reported: several compounds were found to have maximum positive modulation at $\alpha 7$ nAChRs greater than 500% (till 1000%) at 10 μM . Other compounds showed maximum negative modulation of $\alpha 5$ GABA_A-Rs from 5 to 50% at

10 μM . Behavioral tests were performed to evaluate the effect on memory: the compounds of the invention exhibited activity in the radial arm maze paradigm in a range between 0.1 and 10 mg/kg i.p. The tested compounds did not disrupt rotarod performance, thus the possible CNS-depressant effect being excluded.


2.3 Selective $\alpha 5$ GABA_A agonists

Based on studies [69] that linked the age-related cognitive decline and schizophrenia to a reduction of hippocampal expression of $\alpha 5$ subunit of the GABA_A-R, it has been suggested the usefulness of $\alpha 5$ -agonists in the treatment of CNS disorders. Agenebio, Inc. filed two applications in this field [70,71]. In these patents, the preferred compounds with benzodiazepine or pyridazine scaffold (Figure 4) showed an EC_{50} that induced greater than 5% potentiation of the GABA-evoked chlorine current, showing a strong positive allosteric modulatory effect on the $\alpha 5$ GABA_A-Rs.


2.4 Selective $\alpha 2/\alpha 3$ GABA_A agonists

A series of cinnoline and fused quinoline derivatives have been claimed by Astrazeneca AB as GABA_A-R modulators [72-75]. The inventions disclosed derivatives able to modulate the function and activity of GABA and GABA_A-Rs in mammalian subjects, to treat anxiety disorders, cognitive disorders associated with mood and schizophrenia. The therapeutic effect of certain compounds as $\alpha 2/\alpha 3$ GABA_A agonists, in the cognitive impairment associated with schizophrenia, may be demonstrated by using the EEG protocol. These compounds attenuated the high-frequency EEG deficits present in schizophrenic patients. In these international applications, [72-75], GABA_A-R binding assay was performed as reported in Table 4.


A patent application from the Zurich University [76] reported to the use of $\alpha 2/\alpha 3$ GABA_A agonists or partial agonists for the treatment of neuropathic pain. *In vivo* tests to assess the sensitivity to tonic nociceptive stimulation (formalin test) and the pro- or antinociceptive effect in the chronic constriction injury (CCI) model were reported for selected known



Compound 7
WO2012068149 [70]
GABA $\alpha 5$ EC₅₀ % potentiation = 11.1



Compound 4
WO2012068161 [71]
GABA $\alpha 5$ EC₅₀ % potentiation = 42



Compound 27
WO2012068161 [71]
GABA $\alpha 5$ EC₅₀ % potentiation = 30.5

Figure 4. Examples of compounds claimed by Agenebio, Inc.

Table 4. A list of the patents and representative compounds (Astrazeneca AB).

Patent	Compounds*	R ₁	R ₂	R ₃	K _i (nM)
WO2007073283 [72]	64	H		(CH ₂) ₂ CH ₃	$\alpha 2 = 0.144$
WO2008155573 [73]	- [‡]	H		CH ₂ CH ₃	$\alpha 2 = 0.301$
WO2011021979 [74]	I	F			$\alpha 1 = 0.11 \pm 0.03$ $\alpha 2 = 0.65 \pm 0.45$ $\alpha 3 = 0.99 \pm 0.16$ $\alpha 5 = 35.3 \pm 8.5$ $\alpha 2 = 0.774$
WO2008155572 [75]	- [‡]				

*Original number compound used in the cited patents: selection, made by the authors, of the most representative structures.

[‡]Number not reported.




Figure 5. Examples of compounds claimed by Universitat Zurich.

Table 5. A list of the patents and representative compounds (Cook and Wisys).

Patent	Compounds	R	X	K_i (nM)			
				$\alpha 1$	$\alpha 2$	$\alpha 3$	$\alpha 5$
US2010317619 [77]	XHe-II-53	H	CH	287	45	96	138
	JY-XHe-053	H	CF	21.99	12.34	34.9	0.671
	HZ166	H	N	118	148	365	76.88
US7618958 [78]	SH-053-s-CH₃	CH ₃	CH	Anxiolytic activity without suppressing locomotor activity 56 – 100 mg/kg			

compounds, L838417, TPA023, CL218872, SL651498, Ocinaflon (10 mg/kg p.o.) versus diazepam (0.09 mg/kg i.t. or 10 mg/kg p.o.) (Figure 5). For some of these compounds, detailed information is available in the references cited in the same patent and in the recent literature [21].


James Cook and Wisys Technology Foundation have patented [77,78] a series of compounds with benzodiazepine scaffold fused with a heterocyclic five-membered ring (Table 5), with selective agonist efficacy at GABA_A $\alpha 2/\alpha 3$ in comparison with $\alpha 1$, despite the high affinity to all subtype receptors.

Table 6. A list of the patents and representative compounds (Ferrer Internacional SA).

Patent	Compounds*	R ₃	R ₇	K _i (nM)	
				α1	α2
EP1648896 [79]	15	NO ₂		11.1	295.8
EP1648897 [80]	19			0.5	4520
EP1899343 [81]	2			2.1	20
WO2008015253 [82]	5	NO ₂		- [‡]	-

*Original number compound used in the cited patents: selection, made by the authors, of the most representative structures.

[‡]Only specific binding, expressed as % inhibition, is reported (98.2% at 10⁻⁵ M). No IC₅₀ or K_i values are reported.



Compound 15 α1 affinity I% = 87.3
US20100168099 (Ferrer Internacional SA) [83]

Figure 6. Examples of known compounds claimed by Ferrer Internacional SA.

Cook and co-workers reported in a US application [77] methods for suppression, alleviation and prevention of the neuropathic and inflammatory pain. Preferred compounds (XHe-II-53, JY-XHe-053, and HZ166) were tested (8 – 150 mg/kg) for the ability to suppress the pain (thermal hyperalgesia and

mechanical sensitivity) in the chronic constriction injury (CCI) and the inflammatory pain with the formalin test models. The ability of these compounds to suppress pain with minimal ataxic and sedative effects is reflecting their selectivity for α2 or α3 compared to α1.

For the treatment of anxiety, Wisys Technology Foundation has patented [78] a series of compounds tested in a rodent model of anxiety and locomotor activity. The compound SH-053-*s*-CH₃ showed anxiolytic activity without suppressing locomotor activity from 56 until to 100 mg/kg.

2.5 Selective α1 GABA_A agonists

A series of patents claiming several bicyclic heteroaromatic compounds with pyrazolopyrimidine, imidazopyrimidine, imidazopyridine, imidazopyridazine and quinolone scaffolds were registered by Ferrer Internacional S.A. [79-87]. The inventions describe novel classes of subtype-selective α1 relative to α2 GABA_A-R ligands, useful in the treatment and prevention of sleep disorders, insomnia and epilepsy. Many of the novel compounds with pyrazolopyrimidine scaffold (Table 6) [79-82] and the quinolone derivatives (Figure 6) [83] were evaluated *in vitro* and *in vivo*. Good α1 affinity values were evidenced and the *in vivo* effects were assessed by predictive sedation-hypnosis tests in




Figure 7. Examples of compounds claimed by Ferrer Internacional SA.

mice (expressed as percentage of crossings of treated animals versus controls, 89 – 95%) with respect to the reference compound zaleplon (84.9%).

As concerning the imidazole derivatives (Figure 7) in which the heterocyclic ring is variously fused with pyridine, pyrimidine and pyridazine moieties, the *in vitro* and *in vivo* tests were reported in four patents [84–87]. Certain compounds exhibited high selectivity for the $\alpha 1$ GABA_A subtype receptors with respect to the $\alpha 2$ ones, suggesting their possible use in diseases or conditions in which preferential activity on the $\alpha 1$ receptors is desirable, such as insomnia, anesthesia, induction of sleep and sedation. Affinity data were expressed as percentage inhibition (I%) at 10^{-5} for $\alpha 1$ and for $\alpha 2$ subunits and the percentage inhibition of motor activity was in the 85 – 92% range.

3. GABA_A receptor modulators

Many companies and institutions reported in several patents on ligands binding to the GABA_A/Bz site that could be used in the treatment and/or prevention of a variety of disorders

of the central nervous system in particular in anxiety and related diseases. *In vitro* inhibition of ^3H -flunitrazepam (^3H -FNM) binding was performed and the affinity value of the tested substance, which inhibits the specific binding of ^3H -FNM by 50%, was given as IC_{50} or K_i values. All reported compounds may be also useful in their labeled form as radiotracers for positron emission tomography (PET) imaging or for single photon emission computerized tomography (SPECT).

Neurosearch has filed a series of 17 [88–104] patents concerning novel benzimidazole derivatives (Table 7) and 4 patents [105–108] describing imidazole derivatives (Table 8), active from the submicromolar to the picomolar range (IC_{50} 0.10 – 0.00029 μM).

Neurogen published 11 patents and/or applications [109–119] in which are reported numerous heterocyclic compounds (around 2400 derivatives) exhibiting K_i values in the range of 1 μM – 10 nM. To rationalize all these compounds we have summarized the most representative chemical scaffolds and structures in Figures 8, 9 [109,116–119], in Table 9 [110,113–115,120], Table 10 [111] and Table 11 [112]. In Table 9, for the sake of simplicity, we also report the structures described by Yuelian, in the patent


Table 7. A list of the patents and representative compounds (Neurosearch).










Patent	Compounds*	X	Y	R ₁	R ₅	R ₇	IC ₅₀ (μM) I% [‡]
WO2006111517 [88]	23	CH	CH		CH ₃	H	0.0026
WO2006111516 [89]	22a	CH	CH			H	0.0021
WO2006108800 [90]	[§]	CH	CH			H	0.0048
US2006148856 [91]	[§]	CH	CH			H	75%
WO2007065864 [92]	12g	CH	CH			H	0.0026
WO2007110374 [93]	9aac	CH	CH			H	0.00065
US2007021482 [94]	6	CH	CH	H			0.0042
WO2010055124 [95]	8a	CH	CH			H	0.0085
WO2010055125 [96]	8f	CH	C-F			H	0.0026
WO2010055126 [97]	8a	N	CH			H	0.0049
WO2010055127 [98]	8a1	CH	N			H	0.019
WO2010055128 [99]	7d	CH	C-F			H	0.00029

*Original number compound used in the cited patents: selection, made by the authors, of the most representative structures.

[‡]Specific binding (I%) must be obtained, before calculation of IC₅₀.[§]Number not reported.

Table 7. A list of the patents and representative compounds (Neurosearch) (continued).



Patent	Compounds*	X	Y	R ₁	R ₅	R ₇	IC ₅₀ (μM) I% [‡]
WO2010055129 [100]	7a	CH	C-F			H	0.00049
WO2010055130 [101]	7a	N	CH			H	0.0023
WO2010055131 [102]	7g	N	CH			H	0.0013
WO2010055132 [103]	7a	CH	N			H	0.0012
WO2010055133 [104]	7b	CH	N		H	H	0.016

*Original number compound used in the cited patents: selection, made by the authors, of the most representative structures.

[‡]Specific binding (I%) must be obtained, before calculation of IC₅₀.

[§]Number not reported.

application [120] because of the similarity of the nucleus. Preferred compounds of this inventions exhibited $K_i < 100$ nM and the most preferred ones had K_i values < 10 nM. In Table 11 we report three compounds and the most representative general structures chosen among the numerous derivatives reported in the considered patent [112].

Helicon filed patent applications on pyrazoloquinolines [121,122], pyrazolonaphthyridines [123], and dipyrizolopyridines [124]. General binding data are reported and expressed as percentage of inhibition (I%) (Table 12).








A series of quinolone derivatives fused with isothiazole and/or isoxazole rings were registered by Forskarpatent I Syd AB [125] together with their binding mode in a pharmacophoric model. The affinity for GABA_A/Bz (rat cortical membranes) was also measured. The K_i range of these novel compounds was of 1.9 – 18 nM and the company claimed a method for treating anxiolytic, anticonvulsant, sedative-

hypnotic, and myorelaxant conditions in mammals, including humans (Figure 10).

4. Labeled compounds

Concert Pharmaceutical, Inc. patented the deuterated form of several known compounds, since they show a higher metabolic stability but a comparable pharmacological activity with respect to non-deuterated analogs. The determination of metabolic stability was performed *in vitro*, evaluating the “percentage parent remaining” (% PR) that refers to the percentage of starting material remaining at a specified time point (i.e., 30 min). Concert Pharm., in the field of GABA_A ligands seems to be a newcomer and filed five patents [126-130] in which reported several deuterated analogs in the “various possible position” of the considered structures. The deuterated analogs of TPA023 ($\alpha 1$ antagonist; $\alpha 2/\alpha 3$ partial


Table 8. A list of the patents and representative compounds (Neurosearch).

				
Patent	Compounds*	R ₁	R ₂	IC ₅₀ (μM) [‡]
WO2007042543 [105]	-§		CN	0.10
WO2007042544 [106]	-§			0.017
WO2007042545 [107]	11a	-COOC ₂ H ₅		0.024
WO20070472546 [108]	14			0.0027

*Original number compound used in the cited patents: selection, made by the authors, of the most representative structures.

[‡]Specific binding (1%) must be obtained, before calculation of IC₅₀.

§Number not reported.



WO2006093911 [109] (Neurogen)

R = alkyl; R₁ = CN, F; X = S, O

K_i < 1 μM

Figure 8. Example of compound claimed by Neurogen.

agonist), NS11394 (α3 agonist), α5IA (α5 inverse agonist) L838417 (α1 antagonist; α2/α3/α5 agonist), and pagoclone (α3 full agonist; α1/α2/and α5 partial agonist) are shown in Figure 11.

An important aspect developed by GE Healthcare Ltd is related to compounds useful for *in vitro* diagnostics and *in vivo* imaging of the GABA_A-Rs. In particular, these inventions [131,132] deal with quinoline and carboline derivatives showing K_i value ≤ 20 nM at the GABA_A/Bz site from rat cerebellar membranes. It was claimed that these novel

compounds may be prepared with a detectable label, for example, ¹⁸F for PET or SPECT imaging methods. In Figure 12 are reported the only two labeled synthesized compounds claimed in this patent.

5. Patents of natural products and derivatives

Wien University has filed a patent application [133] for piperine derivatives as new anxiolytics with significantly reduced sedative properties without affect transient receptor potential vanilloid 1 (TRPV1). SCT-64 (ex 35) and SCT-66 (ex 36) (Figure 13) show dose-dependent anxiolytic activity at 0.3 – 10 mg/kg in elevated plus maze (EPM) test.

6. Expert opinion

This review presents an overview of the most interesting GABA_A-R modulators patented starting with 2006 till the present period, and can be considered an update of the previously published reviews [134,135].

The Bz-binding site on GABA_A-R has historically received much attention and since 1980 century many efforts were made to develop a pharmacophore/receptor model for agonists, antagonists and inverse agonists, by using a variety of

















Figure 9. Other compounds claimed by Neurogen.

Table 9. A list of the patents and representative compounds (Neurogen and Xu Yuelian).

Patent	Compounds*	R	R ₁	R ₂
WO2006078891 Neurogen [110]	63		F	H
	73		F	H
	79		F	H
	90		F	H
	96		F	H







*Original number compound used in the cited patents: selection, made by the authors, of the most representative structures.

Table 9. A list of the patents and representative compounds (Neurogen and Xu Yuelian) (continued).

				
Patent	Compounds*	R	R ₁	R ₂
US2006247245 Xu Yuelian [120]	102		F	H
	Ex 5		F	H
	Ex 7		H	H
	Ex 9		F	H
EP1880998 Neurogen [113]	106		H	F
	130		F	H
	186		F	H
US7271170 Neurogen [114]	213		H	F
US20090023737 Neurogen [115]	111		H	F
	126		H	F
	128		H	F
			H	F













*Original number compound used in the cited patents: selection, made by the authors, of the most representative structures.

Table 10. A list of the patents and representative compounds (Neurogen).

<div>  </div>			
Patent	Compounds*	R	R ₁
WO2006052546 [111]	106		F
	125		F
	215		F
	217		F
	307		F


*Original number compound used in the cited patents: selection, made by the authors, of the most representative structures.






Table 11. A list of the patents and representative compounds (Neurogen).

<div>  </div>			
Patent	Compounds*	R	R ₁
US20060014746 [112]	Ex 9		
	Ex 11		
	Ex 13		
General structures in US20060014746 [112]		     	Aryl/Heteroaryl (further substituted)

*Original number compound used in the cited patents: selection, made by the authors, of the most representative structures.

Table 12. A list of the patents and representative compounds (Helicon).




Patent	Compounds*	A	R ₃	IC ₅₀ (nM) or I% [‡]
WO2008154442 [121]	45			< 1.0
WO2008154438 [122]	19a		H	< 1.0
WO2008154447 [123]	6c		H	< 1.0
WO2012051213 [124]	6b		H	> 80%

*Original number compound used in the cited patents: selection, made by the authors, of the most representative structures.

[‡]Specific binding must be obtained, before calculation of IC₅₀.

I%: Percentage of inhibition at 0.1 μM.



WO2009123536 [125] (Forskapatent I Syd AB)

X = S, O

R₁ = H, CH₃, OCH₃, NO₂, Br, C₂H₅, C₃H₇,

R₂ = PhCH₃, PhBr, NHCOCH₃

K_i range 1.9 – 18 nM

Figure 10. Examples of compounds claimed by Forskopatent I Syd AB.

techniques (e.g., chemical synthesis, radioligand binding, and receptor mapping) affording thus Cook's model [136]. The determination of the crystal structure of water-soluble acetylcholine binding protein (AChBP) [137] has generated much interest also for the study of the GABA_A-R, and several comparative modeling studies have been proposed for the last one [138,139]. At the same time the discovery of molecular genetics and pharmacological approaches permitted to

elucidate the relationship between the α-subunit and the pharmacological effect of classical benzodiazepines, and to develop selective anxiolytic, anticonvulsant, myorelaxant, sedative and promnemonics drugs. At the present it is particularly intriguing the use of the α-subtype selective ligands as synergic compounds in multi-targeted therapy for CNS diseases.

It is interesting to highlight that the majority of the patents, in the period 2006 – 2012, have been filed by companies (e.g., Hoffmann La-Roche, Neurogen Corp., Neurosearch A/S, and Wisys Technology Foundation, Inc.), extensively engaged in this research field. The α-subtype-selective ligands, developed by these companies, are claimed in the reviewed patent applications, and represent around 70% of the considered patents. Companies such as Ferrer Internacional S.A., Helicon Therapeutics, Inc., Agenebio, Inc., Astrazeneca AB, Concert Pharmaceutical, Inc., GE Healthcare Ltd, and some University, represent the remaining 30%, and are newcomers in this field.

The structural heterogeneity of the compounds reported in the reviewed patents does not permit to individuate a pharmacophore moiety for subtype-selective ligands. The novel compounds claimed in these patents are mainly represented by heterocycles (mono- or bicyclic, eventually further substituted with other ring systems), while the previously described





Figure 11. Example of known compounds claimed from Concert Pharmaceutical.





Figure 12. Examples of compounds claimed from GE Healthcare Ltd.

benzodiazepine receptor ligands showed a planar nitrogen polycyclic scaffold. Thus, a major conformational flexibility in the structure seems to be tolerated for binding on GABA_A-R. For example Hoffmann La Roche “simplified” the rigid tetracyclic scaffold (imidazotriazolobenzodiazepine reported in the 2006 and 2007 patent applications), which led to isoxazole and triazole derivatives.

In addition to several patent applications claiming compounds acting as no-selective GABA_A-R modulators, most of the reviewed patents highlighted that different types of memory deficits related to AD, DS, mood disorders, schizophrenia and age-related cognitive decline, may be treated using $\alpha 5$ -inverse agonists and/or $\alpha 5$ -agonists. Moreover, taking into account that many neurotransmitters are involved in neurodegenerative



WO20110800313 [133] (Universitat Wien)

R = R₁ = *n*-Pr SCT-64 (ex 35)R = R₁ = *i*-Bu SCT-66 (ex 36)

Figure 13. Example of compound claimed by Universitat Wien.

diseases, the use of a dual approach (allosteric modulators of $\alpha 7$ -nAChR and/or $\alpha 5$ -GABA_A-Rs) as claimed from The Regents of the University of California, might be a therapeutically relevant modality to ameliorate CNS disorders. The enhancer cognition topic covers a wide part of the research by the drug companies, as shown by the high number of filed patents.

Another attractive aspect that stands out in this review is the use of $\alpha 2/\alpha 3$ -selective ligands for the prevention or

suppression of neuropathic pain in addition to anxiolytic effects, which represents an intriguing approach, whose research is still in progress.

It is important to point out that the label strategy is another topic reported in several patents, either for improving pharmacokinetic properties without impairing pharmacodynamics properties or for generating diagnostic tools.

All these data show that since 2000 the study and development of subtype-selective receptor ligands is in progress with the aid of classic or more modern approaches. The promising aspect that arises is referred to the possibility to treat particular deficits that are not directly related to GABAergic neurotransmission.

Declaration of interest

This work was supported by a grant from the Italian Ministry for University and Research (MIUR). The authors state no conflict of interest and have received no payment in preparation of this manuscript.

Bibliography

Papers of special note have been highlighted as either of interest (●) or of considerable interest (●●) to readers.

- Olsen RW, Sieghart W. GABAA Receptors: subtypes provide diversity of function and pharmacology. *Neuropharmacology* 2009;56:141-8
- Mohler H. GABAA receptor diversity and pharmacology. *Cell Tissue Res* 2006;326:505-16
- Olsen RW, Sieghart W. International union of pharmacology. LXX. subtypes of gamma-aminobutyric acid receptors: classification on the basis of subunit composition, pharmacology and function. Update 10.1124/pr.108.00505. *Pharmacol Rev* 2008;60:243-60
- Uusi-Oukari M, Korpi ER. Regulation of GABAA receptor subunit expression by pharmacological agents. *Pharmacol Rev* 2010;62:97-135
- Atack JR. The benzodiazepine binding site of GABAA receptors as a target for the development of novel anxiolytics. *Expert Opin Investig Drugs* 2005;14:601-18
- McKernan RM, Rosahl TW, Reynolds DS, et al. Sedative but not anxiolytic properties of benzodiazepine are mediated by the GABAA receptor $\alpha 1$ subtype. *Nat Neurosci* 2000;3:587-92
- Atack JR. GABAA Receptor subtype-selective modulators. I. 2/3-Selective agonists as non-sedating anxiolytics. *Curr Top Med Chem* 2011;11:1176-202
- Atack JR. GABAA Receptor subtype-selective modulators. II. 5-selective inverse agonists for cognition enhancement. *Curr Top Med Chem* 2011;11:1203-14
- Vinkers CH, Mirza NR, Olivier B, Kahn RS. The inhibitory GABA system as a therapeutic target for cognitive symptoms in schizophrenia: investigational agents in the pipeline. doi:10.1517/13543784.2010.513382. *Expert Opin Investig Drugs* 2010;19:1217-33
- Charych EI, Liu F, Moss SJ, Brandon NJ. GABAA receptors and their associated proteins: implications in the etiology and treatment of schizophrenia and related disorders. *Neuropharmacology* 2009;In Press; Corrected Proof
- Vollenweider I, Smith KS, Keist R, Rudolph U. Antidepressant-like properties of $\text{I}\pm 2$ -containing GABAA receptors. *Behav Brain Res* 2011;217:77-80
- Engin E, Liu J, Rudolph U. $\text{I}\pm 2$ -containing GABAA receptors: A target for the development of novel treatment strategies for CNS disorders. *Pharmacol Ther* 2012;136:142-52
- Smith KS, Rudolph U. Anxiety and depression: mouse genetics and pharmacological approaches to the role of GABAA receptor subtypes. *Neuropharmacology* 2012;62:54-62
- Zeilhofer HU, Mohler H, Di Lio A. GABAergic analgesia: new insights from mutant mice and subtype-selective agonists. *Trends Pharmacol Sci* 2009;30:397-402
- Di Lio A, Benke D, Besson M, et al. HZ166, a novel GABAA receptor subtype-selective benzodiazepine site ligand, is antihyperalgesic in mouse models of inflammatory and neuropathic pain. *Neuropharmacology* 2011;60:626-32
- Knabl J, Zeilhofer UB, Crestani F, et al. Genuine antihyperalgesia by systemic diazepam revealed by experiments in GABAA receptor point-mutated mice. *Pain* 2009;141:233-8
- Rudolph U, Knoflach FDR. Beyond classical benzodiazepines: novel therapeutic potential of GABAA receptor subtypes. 2011;10:685-97
- Mirza NR, Munro G. The role of GABAA receptor subtypes as analgesic targets. *Drug News Perspect* 2010;23:351-60

19. Munro G, Ahring PK, Mirza NR. Developing analgesics by enhancing spinal inhibition after injury: GABAA receptor subtypes as novel targets. *Trends Pharmacol Sci* 2009;30:453-9
20. Munro G, Lopez-Garcia JA, Rivera-Arconada I, et al. Comparison of the Novel Subtype-Selective GABAA Receptor-Positive Allosteric Modulator NS11394 [3'-(1-Hydroxy-1-methyl-ethyl)-benzoimidazol-1-yl]-biphenyl-2-carbonitrile] with Diazepam, Zolpidem, Bretazenil, and Gaboxadol in Rat Models of Inflammatory and Neuropathic Pain. *J Pharmacol Exp Ther* 2008;327:969-81
21. Zeilhofer HU, Benke D, Yevenes GE. Chronic pain states: pharmacological strategies to restore diminished inhibitory spinal pain control. *Annu Rev Pharmacol Toxicol* 2012;52:111-33
- **A comprehensive review that describes the relationship between positive allosteric modulators at GABA_A-Rs and pain.**
22. Koh MT, Rosenzweig-Lipson S, Gallagher M. Selective GABAA alpha5 positive allosteric modulators improve cognitive function in aged rats with memory impairment. *Neuropharmacology* 2013;64:145-52
23. Braudeau J, Delatour B, Duchon A, et al. Specific targeting of the GABA-A receptor alpha5 subtype by a selective inverse agonist restores cognitive deficits in Down syndrome mice. *J Psychopharmacol* 2011;25:1030-42
24. Mohler H. Cognitive enhancement by pharmacological and behavioral interventions: the murine Down syndrome model. *Biochem Pharmacol* 2012;84:994-9
25. Ng HJ, Whittemore ER, Tran MB, et al. Nootropic alpha7 nicotinic receptor allosteric modulator derived from GABAA receptor modulators. *Proc Nat Acad Sci USA* 2007;104:8059-64
- **An interesting work that describes the importance of the dual approach on GABA_A receptor and nicotinic receptor.**
26. Liu XF, Chang H-F, Schmiesing RJ, et al. Developing dual functional allosteric modulators of GABAA receptors. *Bioorg Med Chem* 2010;18:8374-82
- **An interesting work that describes the importance of the dual approach on the same GABA_A receptor.**
27. la Fougere C, Rominger A, Forster S, et al. PET and SPECT in epilepsy: a critical review. *Epilepsy Behav* 2009;15:50-5
28. Hoepfing A, Diekers M, Deuter-Conrad W, et al. Synthesis of fluorine substituted pyrazolopyrimidines as potential leads for the development of PET-imaging agents for the GABAA receptors. *Bioorg Med Chem* 2008;16:1184-94
29. Hoffmann-La Roche, Inc. Substituted imidazo[1,5-a][1,2,4]triazolo[1,5-d][1,4] benzodiazepine derivatives. US2006079507; 2006
30. Hoffmann-La Roche, Inc. Substituted imidazo[1,5-a][1,2,4]triazolo[1,5-d][1,4] benzodiazepine derivatives. US2006084642; 2006
31. Hoffmann-La Roche, Inc. Substituted imidazo[1,5-a][1,2,4]triazolo[1,5-d][1,4] benzodiazepine derivatives. US2006128691; 2006
32. Hoffmann-La Roche, Inc. Halogen substituted benzodiazepine derivatives. WO2006045429; 2006
33. Hoffmann-La Roche, Inc. Imidazobenzodiazepine derivatives. WO2007042421; 2007
34. Hoffmann-La Roche, Inc. Aryl-isoxazol-4-yl-imidazole derivatives. WO2007074078; 2007
35. Hoffmann-La Roche, Inc. Aryl-isoxazol-4-yl-imidazo[1,2-a]pyridine useful for the treatment of Alzheimer's diseases via GABA receptors. WO2007082806; 2007
36. Hoffmann-La Roche, Inc. Aryl-isoxazol-4-yl-imidazo[1,5-a]pyridine derivatives. WO2007074089; 2007
37. Hoffmann-La Roche, Inc. Aryl-isoxazolo-4-yl-oxadiazole derivatives. WO2007071598; 2007
38. Hoffmann-La Roche, Inc. 3-Aryl-isoxazole-4-carbonyl-indole derivatives. US2007105922; 2007
39. Hoffmann-La Roche, Inc. Isoxazolo derivatives. US2007066668; 2007
40. Hoffmann-La Roche, Inc. Aryl-4-ethynyl-isoxazole derivatives. WO2007137954; 2007
41. Hoffmann-La Roche, Inc. Isoxazole-imidazole derivatives. WO2009000662; 2009
42. Hoffmann-La Roche, Inc. Isoxazolo-pyridine derivatives. WO2009071476; 2009
43. Hoffmann-La Roche, Inc. Isoxazolo - pyridine derivatives. US2009143385; 2009
44. Hoffmann-La Roche, Inc. Isoxazolo-pyrazine derivatives. US2009143407; 2009
45. Hoffmann-La Roche, Inc. Isoxazolo-pyridazine derivatives. WO2010127968; 2010
46. Hoffmann-La Roche, Inc. Hydroxymethyl isoxazole derivatives as GABAA modulators. WO2010112475; 2010
47. Hoffmann-La Roche, Inc. Isoxazole-thiazole derivatives as GABAA receptor inverse agonist for use in the treatment of cognitive disorders. WO2010127974; 2010
48. Hoffmann-La Roche, Inc. Isoxazolo-pyrazole derivatives. WO2010127975; 2010
49. Hoffmann-La Roche, Inc. Isoxazolo-pyridine derivatives. WO2010127976; 2010
50. Hoffmann-La Roche, Inc. Isoxazolo-pyridine derivatives as GABA modulators. WO2010127978; 2010
51. Hoffmann-La Roche, Inc. Isoxazolo-pyrazine derivatives. US2010256154; 2010
52. Hoffmann-La Roche, Inc. Isoxazoles/O-pyridine derivatives with ethyl and ethenyl linker. US2010216845; 2010
53. Hoffmann-La Roche, Inc. Isoxazole-isoxazoles and isoxazole-isothiazoles. US2010210651; 2010
54. Hoffmann-La Roche, Inc. Novel triazole compounds III. WO2012076590; 2012
55. Hoffmann-La Roche, Inc. Novel triazole compounds I. WO2012062687; 2012
56. The Governing Council of the University of Toronto. Methods for the prevention and/or treatment of memory. WO2012051707; 2012
57. Atack JR, Bayley PJ, Seabrook GR, et al. L-655,708 enhances cognition in rats but is not proconvulsant at a dose selective for [alpha]5-containing GABAA receptors. *Neuropharmacology* 2006;51:1023-9
58. Atack JR, Maubach K, Wafford KA, et al. In vitro and in vivo properties of 3-tert-butyl-7-(5-methylisoxazol-3-yl)-2-(1-methyl-1H-1,2,4-triazol-5-ylmethoxy)-pyrazolo[1,5-d][1,2,4]triazine (MRK-016), a GABAA Receptor alpha5 subtype

- selective inverse agonist. *J Pharmacol Exp Ther* 2009;331:470-84
59. Cambridge Enterprise Ltd. Use of GABAA receptor antagonists to treat cognitive impairment in patients with psychiatric conditions. WO2009016329; 2009
 60. Savic MM, Obradovic DI, Ugresic ND, et al. Bidirectional effects of benzodiazepine binding site ligands in the passive avoidance task: differential antagonism by flumazenil and beta-CCt. *Behav Brain Res* 2005;158:293-300
 61. Centre National de la Recherche Scientifique-CNRS. Composition and method for treating cognitive impairments in Down syndrome subject. WO2011024115; 2011
 62. Knust H, Achermann G, Ballard T, et al. The discovery and unique pharmacological profile of RO4938581 and RO4882224 as potent and selective GABAA [alpha] 5 inverse agonists for the treatment of cognitive dysfunction. *Bioorg Med Chem Lett* 2009;19:5940-4
 63. The Board of Trustees of the Leland Stanford Junior University. Cognitive function. US20121574445; 2012
 64. Wisys Technology Foundation, Inc. GABAergic agents to treat memory deficits. US7595395; 2009
 65. Savic MM, Clayton T, Furtmuller R, et al. PWZ-029, a compound with moderate inverse agonist functional selectivity at GABAA receptors containing [alpha]5 subunits, improves passive, but not active, avoidance learning in rats. *Brain Res* 2008;1208:150-9
 66. Han D, Holger Forsterling F, Li X, et al. A study of the structure-activity relationship of GABA A-benzodiazepine receptor bivalent ligands by conformational analysis with low temperature NMR and X-ray analysis. *Bioorg Med Chem* 2008;16:8853-62
 67. Cook James. GABAergic agents to treat memory deficits. US2010130479; 2010
 68. The Regents of the University of California. Substituted heterocycles and their use as allosteric modulators of nicotinic and GABAA receptors. WO2010104843; 2010
 69. The Johns Hopkins University. Methods for characterizing and treating cognitive impairment in aging and disease. WO2007019312; 2007
 70. Agenebio, Inc. Benzodiazepine derivatives, compositions and methods for treating cognitive impairment. WO2012068149; 2012
 71. Agenebio, Inc. Pyridazine derivatives, compositions and methods for treating cognitive impairment. WO2012068161; 2012
 72. Astrazeneca AB. Substituted cinnoline derivatives as GABAA receptor modulators and method for their synthesis. WO2007073283; 2007
 73. Astrazeneca AB. Uses of cinnoline compounds to treat schizophrenia. WO2008155573; 2008
 74. Astrazeneca AB. Cinnoline compounds, their preparation, and their use. WO2011021979; 2011
 75. Astrazeneca AB. Compound and uses thereof - 848. WO2008155572; 2008
 76. Universitat Zurich. Selective therapeutic agents for pain suppression. WO2006061428; 2006
 77. Cook James. Selective agents for pain suppression. US2010317619; 2010
 78. Wisys Technologys Foundation. Stereospecific anxiolytic and anticonvulsant agents with reduced muscle-relaxant, sedative-hypnotic and ataxic effects. US7618958; 2009
 79. Ferrer Internacional SA. N-[3-(3-substituted-pyrazolo[1,5-a]pyrimidin-7-yl)phenyl]-sulfonamides, end composition, and methods related thereto. EP1648897; 2008
 80. Ferrer Internacional SA. 7-Substituted 3-nitropyrazolo[1,5-a]pyrimidines. EP1648896; 2008
 81. Ferrer Internacional SA. Halogenated pyrazolo[1,5-a]pyrimidines processes, uses as GABAA receptors ligands, compositions and intermediates. EP1899343; 2010
 82. Ferrer Internacional SA. Pyrazolo[1,5-a]pyrimidines processes, uses and compositions. WO2008015253; 2008
 83. Ferrer Internacional SA. 1H-Quinolin-4-one compounds, with affinity for the GABA receptor, processes, uses and compositions. US2010168099; 2010
 84. Ferrer Internacional SA. Imidazo[1,2-a]pyridine compounds, compositions, uses and methods related thereto. WO2006051063; 2006
 85. Ferrer Internacional SA. Imidazo[1,2-a]pyridin-3-yl-acetic acid hydrazides, processes for their preparation and pharmaceutical uses thereof. WO2007077159; 2007
 86. Ferrer Internacional SA. N-[3-Imidazo[1,5-a]pyrimidin-4-yl)phenyl]-sulfonamides and N-[3-Imidazo[1,5-a]pyrimidin-4-yl)phenyl]-carboxamides and their use as GABAA receptor modulators. WO2006084835; 2006
 87. Ferrer Internacional SA. Imidazo[1,2-b]pyridazines, their processes of preparation and their use as GABA receptor ligands. WO2007110437; 2007
 88. Neurosearch AS. Benzimidazole derivatives and their use for modulating the GABAA receptor complex. WO2006111517; 2006
 89. Neurosearch AS. Benzimidazole derivatives and their use for modulating the GABAA receptor complex. WO2006111516; 2006
 90. Neurosearch AS. Benzimidazole derivatives and their use for modulating the GABAA receptor complex. WO2006108800; 2006
 91. Neurosearch AS. Benzimidazole derivatives and their use for modulating the GABAA receptor complex. WO2006148856; 2006
 92. Neurosearch AS. Benzimidazole derivatives and their use for modulating the GABAA receptor complex. WO2007065864; 2007
 93. Neurosearch AS. Benzimidazole derivatives and their use for modulating the GABAA receptor complex. WO2007110374; 2007
 94. Neurosearch AS. 1,5,7-Trisubstituted benzimidazole derivatives and their use for modulating the GABAA receptor complex. US2007021482; 2007
 95. Neurosearch AS. Benzimidazole derivatives and their use for modulating the GABAA receptor complex. WO2010055124; 2010
 96. Neurosearch AS. Benzimidazole derivatives and their use for modulating the GABAA receptor complex. WO2010055125; 2010
 97. Neurosearch AS. Benzimidazole derivatives and their use for modulating the GABAA receptor complex. WO2010055126; 2010
 98. Neurosearch AS. Benzimidazole derivatives and their use for modulating

- the GABAA receptor complex. WO2010055127; 2010
99. Neurosearch AS. Benzimidazole derivatives and their use for modulating the GABAA receptor complex. WO2010055128; 2010
 100. Neurosearch AS. Benzimidazole derivatives and their use for modulating the GABAA receptor complex. WO2010055129; 2010
 101. Neurosearch AS. Benzimidazole derivatives and their use for modulating the GABAA receptor complex. WO2010055130; 2010
 102. Neurosearch AS. Benzimidazole derivatives and their use for modulating the GABAA receptor complex. WO2010055131; 2010
 103. Neurosearch AS. Benzimidazole derivatives and their use for modulating the GABAA receptor complex. WO2010055132; 2010
 104. Neurosearch AS. Benzimidazole derivatives and their use for modulating the GABAA receptor complex. WO2010055133; 2010
 105. Neurosearch AS. Imidazole derivatives and their use for modulating the GABAA receptor complex. WO2007042543; 2007
 106. Neurosearch AS. Imidazole derivatives and their use for modulating the GABAA receptor complex. WO2007042544; 2007
 107. Neurosearch AS. Imidazole derivatives and their use for modulating the GABAA receptor complex. WO2007042545; 2007
 108. Neurosearch AS. Imidazole derivatives and their use for modulating the GABAA receptor complex. WO2007042546; 2007
 109. Neurogen Corp. Thiazolylmethyl and oxazolylmethyl heteroaryl derivatives. WO2006093911; 2006
 110. Neurogen Corp. Imidazolylmethyl and pyrazolylmethyl heteroaryl derivatives. WO2006078891; 2006
 111. Neurogen Corp. Pyrazolylmethyl heteroaryl derivatives. WO2006052546; 2006
 112. Neurogen Corp. Heteroaryl substituted fused bicyclic heteroaryl compounds as GABAA receptor ligands. US2006014746; 2006
 113. Neurogen Corp. Imidazo-pyrimidines and triazolo-pyrimidines: benzodiazepine receptor ligands. EP1880998; 2008
 114. Neurogen Corp. Imidazo-pyrimidines, triazolo-pyrimidines: and related benzodiazepine receptor ligands. US7271170; 2007
 115. Neurogen Corp. Imidazo-pyridazines, triazolo-pyridazines and related benzodiazepine receptor ligands. US20090023737; 2009
 116. Neurogen Corp. Arylacid pyrimidinyl amides, pyridazinyl methyl amides and related compounds. US20061353367; 2006
 117. Neurogen Corp. Heteroaryl fused aminoalkyl imidazole derivatives: selective modulators of GABAA receptors. US2006160842; 2006
 118. Neurogen Corp. Bicyclic and tricyclic heteroaromatic compounds. US2008146546; 2008
 119. Neurogen Corp. Substituted fused pyrroleximes and fused pyrazoleoxyme. US2008032975; 2008
 120. Xu Yuelian. Substituted imidazopyrazine and triazolopyrazine derivatives: GABAA receptor ligands. US2006247245; 2006
 121. Helicon Therapeutics, Inc. Therapeutic pyrazoloquinoline urea derivatives. WO2008154442; 2008
 122. Helicon Therapeutics, Inc. Therapeutic pyrazoloquinoline derivatives. WO2008154438; 2008
 123. Helicon Therapeutics, Inc. Therapeutic pyrazolonaphthyridine derivatives. WO2008154447; 2008
 124. Helicon Therapeutics, Inc. Therapeutic 5,6,5-tricyclic analogs. WO2012051213; 2012
 125. Forskarpatent I SYD AB. New classes of GABAA/BZR ligands. WO2009123536; 2009
 126. Concert Pharmaceutical, Inc. Deuterium-modified triazolo-pyridazine derivatives as GABAA receptor modulators. WO2011005520; 2011
 127. Concert Pharmaceutical, Inc. Substituted benzimidazoles. WO2011047315; 2011
 128. Concert Pharmaceutical, Inc. Substituted triazolo-phthalazine derivatives. WO2011020044; 2011
 129. Concert Pharmaceutical, Inc. Substituted triazolo-pyridazine derivatives. WO2010025407; 2010
 130. Concert Pharmaceutical, Inc. 2-Aminonaphthiridine derivatives. WO2012116288; 2012
 131. Ge Healthcare Ltd. Carbolines and their use as imaging agents. WO2008132454; 2008
 132. GE Healthcare Ltd. Imaging agents. WO2009040377; 2009
 133. Universitat Wien. Novel piperine derivatives as GABAA receptors modulators. WO20110800313; 2011
 134. Cooke AJ, Hamilton MN. alpha-Subunit selective modulators of GABAA receptor function as CNS therapeutics. Expert Opin Ther Patent 2002;12:1491-501
 135. Romanelli MN, Gualtieri F. The quest for the treatment of cognitive impairment: alpha7 nicotinic and alpha5 GABAA receptor modulators. Expert Opin Ther Patent 2007;17:1365-77
 136. Zhang W, Koehler KF, Zhang P, Cook JM. Development of a comprehensive pharmacophore model for benzodiazepine receptor. Drug Des Discov 1995;12:193-248
 137. Brejck K, van Dijk W, Klassen R, et al. Crystal structure of an ACh-binding protein reveals the ligand-binding domain of nicotinic receptors. Nature 2001;411:269-76
 138. Ernst M, Bruckner S, Boresch S, Sieghart W. Comparative Models of GABAA Receptor Extracellular and Transmembrane Domains: important Insights in Pharmacology and Function 10.1124/mol.105.015982. Mol Pharmacol 2005;68:1291-300
 139. Hanson SM, Czajkowski C. Structural mechanisms underlying benzodiazepine modulation of the GABAA receptor. J Neurosci 2008;28:3490-9

Affiliation

Gabriella Guerrini[†] & Giovanna Ciciani

[†]Author for correspondence

Researcher,
Dipartimento di Neuroscienze, Psicologia,
Area del Farmaco e Salute del Bambino,
NEUROFARBA - “Sezione di
Farmaceutica e Nutraceutica”
Università degli Studi di Firenze,
Via Ugo Schiff,6 - 50019
Sesto Fiorentino- Fi, Italy
Tel: +39 055 4573766;
Fax: +39 055 457 3671/3780;
E-mail: gabriella.guerrini@unifi.it